Evaluation of CMV/EBV-CMI in Haploid HSCT
Evaluation of Cytomegalovirus and Epstein-Barr Virus Specific Immune Reformulation in Prophylaxis for Cytomegalovirus in Haploid Hematopoietic Stem Cell Transplantation
The First Affiliated Hospital of Soochow University
60 participants
Aug 13, 2024
OBSERVATIONAL
Conditions
Summary
The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .
Eligibility
Inclusion Criteria3
- All patients were diagnosed with hemopathy.
- All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus.
- All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study.
Exclusion Criteria1
- Patients with any conditions not suitable for the trial (investigators' decision).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06554197